Company Overview
Management
Board of Directors
Partners
Investors
AEROSPAN
NASACORT HFA
Press Releases
PRESS RELEASES
09/20/2012
ACTON PHARMACEUTICALS ANNOUNCES U.S. FOOD AND DRUG ADMINISTRATION APPROVAL FOR AEROSPAN® (flunisolide HFA, 80 mcg) INHALATION AEROSOL FOR ASTHMA
10/25/2011
ACTON PHARMACEUTICALS, INC. ANNOUNCES LICENSE AGREEMENT WITH SANOFI U.S. FOR NASACORT HFA (triamcinolone acetonide) NASAL AEROSOL
10/11/2011
ACTON PHARMACEUTICALS, INC. ANNOUNCES PUBLICATION OF AEROSPAN (flunisolide HFA) PEDIATRIC LINEAR GROWTH STUDY IN ANNALS OF ALLERGY, ASTHMA & IMMUNOLOGY
05/05/2011
ACTON PHARMACEUTICALS, INC. ANNOUNCES ADDITIONS TO THE EXECUTIVE MANAGEMENT TEAM
11/03/2010
ACTON PHARMACEUTICALS, INC. SUBMITS NDA SUPPLEMENT TO FDA FOR AEROSPAN (flunisolide HFA, 80 mcg) INHALATION AEROSOL
11/02/2010
ACTON PHARMACEUTICALS, INC. AWARDED GRANT FOR AEROSPAN (flunisolide HFA, 80 mcg) UNDER THE QUALIFYING THERAPEUTIC DISCOVERY PROJECT
05/24/2010
ACTON PHARMACEUTICALS, INC. FORMS SCIENTIFIC BOARD
01/05/2010
ACTON PHARMACEUTICALS, INC. ANNOUNCES COMPLETION OF $15 MILLION SERIES A FINANCING WITH SEQUOIA CAPITAL
